Heidelberg Pharma Announces Changes to the Executive Management Board
- CEO Dr. Jan Schmidt-Brand to retire
- His successor will be Prof. Dr. Andreas Pahl, Chief Scientific Officer
Heidelberg Pharma AG today announced that Dr. Jan Schmidt-Brand, Chief Executive Officer (CEO) of Heidelberg Pharma AG and Managing Director of the subsidiary Heidelberg Pharma Research GmbH, is planning to retire at the beginning of February 2024 and step down from his positions. The Supervisory Board has appointed Prof. Dr. Andreas Pahl as CEO effective 1st February 2024. Mr. Pahl will also assume the role of Managing Director of the subsidiary.